Mr Jeffrey Trocio
New York (United States of America)
Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
Event: ESC Congress 2017
Topic: Atrial fibrillation (AF)
Session: Bleeding and LAA occlusion
Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Anticoagulation in atrial fibrillation II
ESC 365 is supported by
